The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It

The AI drug discovery field is shifting focus from building the most powerful models to establishing trustworthy, connected biological data foundations. MindWalk Holdings (HYFT) has positioned itself as a leader in this 'context layer' approach with its ReefIQ and LensAI platforms, reporting 52% YoY revenue growth and its first recurring platform contract. The article examines how this represents a maturation of the sector beyond initial hype, comparing MindWalk's strategy to peers like Absci, Recursion, Schrödinger, and Certara.

06/16/2026, 8:45 AM • Benzinga

Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?

Recursion Pharmaceuticals and Schrödinger represent different approaches to AI-driven drug discovery—one biotech-focused with clinical-stage programs, the other software-first with recurring revenue. While both show strong growth (26.9% and 23.3% respectively), Recursion trades at a premium valuation (26.1x P/S) with significant losses and no approved products, while Schrödinger has a lower P/S ratio (4.3x) and improving profitability. The analyst recommends neither stock currently but would choose Schrödinger if forced to pick, citing its established software business and improving financial trajectory.

06/02/2026, 5:12 PM • The Motley Fool

My Top 3 Biotech Stocks for May 2026

With stabilizing interest rates and increased FDA activity, three biotech companies stand out: Schrödinger combines AI-driven drug discovery with established software revenue ($256M in 2025); Sarepta generates nearly $2B in annual product revenue from gene therapy despite ongoing safety concerns around Elevidys; and NRX Pharmaceuticals, a speculative small-cap, has regulatory momentum with FDA decisions expected this summer for depression and suicidality treatments.

05/20/2026, 11:15 AM • The Motley Fool

Global Biosimulation Market Poised for Phenomenal Expansion at a CAGR of ~17% by 2034 | DelveInsight

The biosimulation market is experiencing robust growth, projected to expand from USD 4.7 billion in 2025 to USD 20 billion by 2034 at a CAGR of ~17%. Growth is driven by increasing adoption of model-informed drug development (MIDD), rising complexity of modern therapeutics, regulatory support from FDA and EMA, and the shift toward virtual clinical trials and precision medicine. North America leads the market with 44.24% share, while Asia-Pacific emerges as a major growth contributor.

04/27/2026, 1:00 PM • GlobeNewswire

Materials Informatics Market Size to Hit USD 736.71 Million by 2035

The global materials informatics market is projected to expand at a CAGR of 16.7% from 2026 to 2035, driven by increasing adoption of AI and machine learning in materials research, growing demand for sustainable materials, and digital transformation across automotive, aerospace, and electronics sectors. Machine learning and elements segments currently dominate, while chemicals and electronics segments are expected to show the highest growth rates.

01/02/2026, 3:04 AM • GlobeNewswire

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood's Ark Invest made strategic purchases in three stocks during late December 2025: Circle Internet Group (a stablecoin company), Bullish (a cryptocurrency exchange), and Schrödinger (a healthcare tech firm specializing in drug discovery). While the crypto plays show growth, the analyst expresses cautious optimism, viewing Schrödinger as the most compelling investment due to its expanding software revenue and potential applications.

12/20/2025, 6:15 AM • The Motley Fool